PRINCETON, N.J.--(BUSINESS WIRE)--Certara®, the global leader in model-informed drug development, regulatory science, market access and real-world evidence services, today announced the launch of ...

PRINCETON, NJ--(BUSINESS WIRE)--Certara®, the global model-informed drug development and decision support leader, today announced the launch of Phoenix® 8.2, the ...

RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5. Phoenix is the ...

In-silico bioequivalence approach using Simcyp’s Multi-Phase Multi-Layer Mechanistic Dermal Absorption model successfully replaced in-vivo, clinical studies in FDA ANDA approval PRINCETON, NJ – June ...

Unique capabilities expand the types of drugs, modalities, populations, and development questions modeled using the Simcyp PBPK Simulator Certara’s industry-leading Simcyp PBPK Simulator improves ...

Certara will host a Phoenix® User Group Meeting and lead 15 presentations and poster sessions focusing on the newest applications of model-informed drug development PRINCETON, NJ – Nov. 1, 2018 – ...

Princeton-based Certara, the global model-informed drug development and decision support leader, reported on Tuesday it acquired a range of modeling and simulation technology assets from In Silico ...

Yu-Wei Lin, Zheng Liu and Katrina Hui. – CERTARA-MONASH Princeton-based Certara, a global model-informed drug development, regulatory science, real-world evidence and market access services company, ...

Background: Serdemetan is a compound that can cause replicative stress type responses in tumor cells and it has been administered to patients with solid tumors. ECG data from an ongoing first-in-human ...

Certara®, the global leader in model-informed drug development and regulatory science, today announced that its comprehensive influenza viral kinetic modeling review has just been published in Current ...

Bioavailability of the hedgehog pathway inhibitor GDC-0449 in a phase I pharmacokinetic (PK) study in healthy female subjects. Background: Serdemetan is a compound that can cause replicative stress ...